



Progress Update (PU)

Partner Portal Screen Preview

June 2024

How to use this document

This document is primarily intended for Principal Recipients. Its objective is to provide a preview of the new online screens, as well as the content expected in the Progress Update. Please note that all data included in this document is illustrative and not specific to a particular grant.

Overview of content included in the PU

Tabs included in the PU

PU	Coversheet	Coversheet – view only				
	Programmatic	Impact/Outcome Indicators*	Coverage Elementary Indicators**	Coverage Indicators	Work Plan Tracking Measures (WPTM)	
	Financial	Coversheet	Cash Reconciliation	Open Advances	Expenditure Report	Non-compliant Expenditures
	PSCM & Grant Management	Health Products	Grant & Risk Management	Self-Assessment	LFA Findings & Recommendations	

* Only appears with quarterly reported Outcome Indicators.

** GC7 only.

Executive Summary (view only)

Provide a summary of grant performance (integrating programmatic, finance, procurement, supply chain management, grant and risk management considerations) during the current reporting period ⓘ

Explain any external factors beyond the control of the Principal Recipient that have negatively impacted quality and timely grant delivery during the reporting period ⓘ

Forward-looking assessment of expected implementation progress by module for the coming reporting period

Item Module		PR response
1	Case management	Select
2	Vector control	Select
3	Prevention package for people who use drugs (PUD) and their sexual partners	Select
4	Prevention package for people in prisons and other closed settings	Select
5	Differentiated HIV Testing Services	Select
6	Treatment, care and support	Select
7	TB/HIV	Select
8	TB diagnosis, treatment and care	Select
9	Drug-resistant (DR)-TB diagnosis, treatment and care	Select
10	TB/DR-TB Prevention	Select
11	Key and vulnerable populations (KVP) – TB/DR-TB	Select
12	RSSH: Monitoring and evaluation systems	Select
13	RSSH/PP: Laboratory systems (including national and peripheral)	Select

* Tab only appears with quarterly reported indicators

Impact / Outcome Indicator

> Errors and Warnings

☰ Check data quality

Item	Indicator type ↑	Code	Indicator	Baseline	Baseline Data Source	Target	Results	Action
1	Impact	HIV I-11	HIV I-11 Percentage of people who inject drugs who are living with HIV	N: D: % Year		N: D: % Year	N: D: % Year	Provide results
2	Impact	HIV I-15	HIV I-15 Percentage of prisoners who are living with HIV	N: D: % Year		N: D: % Year	N: D: % Year	Provide results
3	Outcome	HIV O-6	HIV O-6 Percentage of people who inject drugs reporting using sterile injecting equipment the last time they injected	N: D: % Year		N: D: % Year	N: D: % Year	Provide results
4	Outcome	HIV O-12	HIV O-12 Percentage of people who inject drugs who are virologically suppressed	N: D: % Year		N: D: % Year	N: D: % Year	Provide results
5	Outcome	TB O-4	TB O-4 Treatment success rate of patients with RR a	N: D: % Year		N: D: % Year	N: D: % Year	Provide results

< Previous indicator Next indicator >

Close

Impact Indicator

Indicator Code: HIV I-11 HIV I-11 Percentage of people who inject drugs who are living with HIV

Baseline (Date Source): IBBS

N:	D:	% 4.40%	Year 2012	N:	D:	Target %	Year 2024	Refresh
----	----	---------	-----------	----	----	----------	-----------	---------

PR Results (01-Jan-24 to 30-Jun-24)

Result	N:	
	D:	
	%	
	Year	Select
	Data source	

PR Comments

* Tab only appears for GC7

Coverage Elementary Indicator

> Errors and Warnings

☰ Check data quality

Item	Code ↑	Indicator	Results reporting period	Frequency	Scope Of Targets	PR Results	Action
1	CM-1a [D]	Number of all suspected malaria cases that present at public sector health facilities	01-Apr-24 to 30-Jun-24	Quarterly	Geographic National, 100% of national program target		Provide results
2	CM-1a [N]	Number of all suspected malaria cases that received a parasitological test at public sector health facilities	01-Apr-24 to 30-Jun-24	Quarterly	Geographic National, 100% of national program target		Provide results
3	CM-1b [D]	Number of all suspected malaria cases in the community	01-Apr-24 to 30-Jun-24	Quarterly	Geographic National, 100% of		Provide results
4	CM-1b [N]	Number of all suspected malaria cases that received a parasitological test in the community					Provide results
5	CM-2a [D]	Number of confirmed malaria cases at public health facilities (found by both passive and activesurveillance)					Provide results
6	CM-2a [N]	Number of confirmed malaria cases treated who received first-line antimalarial treatment according to national policy at public sector health facilities					Provide results
7	CM-2b [D]	Number of confirmed malaria cases in the community					Provide results

< Previous indicator Next indicator >

Close

Coverage Elementary Indicator

Indicator Code: CM-1b [N] Number of all suspected malaria cases that received a parasitological test in the community

Scope of Targets: Geographic National, 100% of national program target

Cumulation Type: Non cumulative

Related Coverage Indicators

Q1 Jan-2024 to Mar-2024 Q2 Apr-2024 to Jun-2024 S1 Jan-2024 to Jun-2024

PR Results CM-1b Refresh

> **i** Errors and Warnings

☰ Check data quality

Coverage Indicator

Indicator Code: CM-2b

CM-2b Proportion of confirmed malaria cases that received first-line antimalarial treatment in the community

Scope of Targets: Geographic National, 100% of national program target

Cumulation Type: Non cumulative

Baseline (Date Source):

N:

D:

Year

N:

D:

Target(Apr - Jun)

Reverse Indicator: No

	Related Elementary Indicators	Q1 Jan-2024 to Mar-2024	Q2 Apr-2024 to Jun-2024	S1 Jan-2024 to Jun-2024
PR Results	CM-2b [N]	N:	N:	N:
	CM-2b [D]	D:	D:	D:
	%	%	%	%

Refresh

PR Comments ⓘ

WPTM

> Errors and Warnings

☰ Check data quality

Item	Intervention	Activity	Milestone / Targets	Criteria for Completion	Progress Status	Score	PR Comments	
1	Facility-based testing for key population (KP) programs			0 (not started): No progress is shown toward achieving the milestone 1 (started): Key prison authorities were identified, and coordination meetings were conducted to ensure HT service delivery to female prisoners. Reports/minutes from the meetings are available 2 (advancing): Approval for conducting and reporting on HTM activities among female prisoners obtained 3 (completed): Action plan to roll out the HT programs in female prisons drafted and endorsed by the prison authorities	Select			
2	TB screening and diagnosis			0 (not started): No progress is shown toward achieving the milestone 1 (started): Key prison authorities were identified, and coordination meetings were conducted to ensure HT service delivery to female prisoners. Reports/minutes from the meetings are available 2 (advancing): Approval for conducting and reporting on HTM activities among female prisoners obtained. Assessment of the current TB screening services and sample transportation system for female prisoners done. 3 (completed): Action plan to roll out the HT programs in female prisons drafted and endorsed by the prison authorities	Select			

Cover Sheet

>  Errors and Warnings

 Check data quality

Data quality check required

Financial Summary

Cash balance at the end of the period	Time elapsed since start of IP

Exchange rates

Item	Exchange Rate	Exchange rates used by the PR
1	Exchange rate to convert opening cash balance	
2	Exchange rate to convert closing cash balance	
3	Exchange rate to convert total PR cash outflow for the reporting period	
4	Comments on exchange rates	

Cash Reconciliation

Financial Reporting Period
01-Jan-24 to 30-Jun-24

Implementation Period currency
USD

>  Errors and Warnings

 Check data quality

 No errors or warnings

Data Import Wizard

Copy Data

Import

Instructions

Financial Information

Item No.	Description	Regular Funds	Other Non-fungible sources	Total	1. Comment on cash flows 2. Outline the data source(s) 3. Provide any other contextual information
1	PR cash balance				
1.1	PR cash balance: beginning of the current financial reporting period			-	
2	IP Income				
2.1	Disbursements made directly by the Global Fund to the PR		-		
2.2	Disbursements made by the Global Fund through PPM / wambo	-	-	-	
2.3	Other direct disbursements made by the Global Fund	-	-	-	
2A	Total disbursements made by the Global Fund		-		
2.4	Interest received on PR bank accounts			-	
2.5	PR's revenue from income-generating activities and other income (e.g. income from disposal of assets, etc.), if applicable			-	

2B	Total other income for PR	-	-	-	
2.7.1	Refunds received at PR level from third parties			-	
2.7.2	Refunds received from SRs			-	
2.7.3	Tax refunds received (e.g. VAT/other tax returns)			-	
2.7.4	Reimbursement of non-compliant expenditures made into PR account			-	
2C	Total Refunds received	-	-	-	
2.7	Total IP income		-		
3	IP cash outflows				
3.1	PR Payments (including advance payments)			-	
3.2	PPM / wambo payments made by the Global Fund on behalf of the PR	-	-	-	
3.3	Payments to other third parties by the Global Fund on behalf of the PR	-	-	-	
3.4	PR disbursement(s) to sub-recipients			-	
3.5	Bank charges on disbursements and payments for PR			-	
3.6	Total payments and disbursements	-	-	-	
4	Reconciling adjustments: (PR only)				
4.1	Other reconciliation adjustments (including for previous financial reporting periods)			-	
4.2	Net exchange gains/losses on translation of balances			-	
4.3	Total reconciling adjustments	-	-	-	

5	Total cash balance: end of the current financial reporting period				
5.1	Total PR cash balance		-		

Bank Reconciliation Statement Balances

Item No.	Description	Regular Funds	Other Non-fungible sources	Total	1. Comment on cash flows 2. Outline the data source(s) 3. Provide any other contextual information
9.1	PR balance as per bank statements (for information only)				
9.2	Bank reconciliation net amount				
9.3	Variance between bank statement balance and PR cash balance				
9.4	Variance between bank reconciliation statement balance and PR cash balance				

Open Advances

Financial Reporting Period
01-Jan-24 to 30-Jun-24

Implementation Period currency
USD

>  Errors and Warnings

☰ Check data quality

Item No.	Open advances at the end of the current financial reporting period	Regular Funds	Total
14.1	SR advances		-
14.2	PR procurement advances (PPM/Wambo only)		-
14.3	PR other advances (GDF, prepayments, etc.)		-

Detailed Expenditure Reporting

Financial Reporting Period
01-Jan-24 to 30-Jun-24

Implementation Period currency
USD

> ⓘ Errors and Warnings

- Additional columns:
- Absorption rate
 - Cumulative expenditure reported by PR up to the start of the current financial reporting period
 - Cumulative Global Fund validated expenditure up to the start of current financial reporting period
 - Cumulative budget up to end of the financial reporting year
 - Cumulative expenditure at the end of the current financial reporting period
 - Budget vs expenditure variance
 - Absorption
 - Explain cumulative period variances

A. Breakdown by Costing Dimension						
Cost Input	Budget for the current financial reporting year		Expenditure for the current financial reporting period		Budget vs Expenditure variance for the current period	Absorption rate
B. Breakdown by Module / Intervention						
Module	Intervention	Budget for the current financial reporting year		Expenditure for the current financial reporting period		Budget vs Expenditure variance for the current period
C. Breakdown by Implementing Entity						
Implementing Entity	Type of Implementing Entity	Budget for the current financial reporting year		Expenditure for the current financial reporting period		Budget vs Expenditure variance for the current period

Non-compliant Expenditures

Financial Reporting Period
01-Jan-24 to 30-Jun-24

Implementation Period currency
USD

>  Errors and Warnings

 Check data quality

Principal Recipient non-compliant expenditures in IP currency

Regular Funds

Item No. Description		Current financial reporting period	1. Comment on cash flows 2. Outline the data source(s) 3. Provide any other contextual information
10.1	Non-compliant expenditures validated for the current financial reporting period		

Health Products

>  Errors and Warnings

 Check data quality

A. Price Quality Reporting

Description	Principal Recipient	Comments
Is the Price Quality Reporting (PQR) updated with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR (if applicable)? If health products procurement information has not been entered into the PQR, please explain why. ! For further guidance on PQR data entry, please refer to the Guide to Global Fund Policies on Procurement and Supply Management of Health Products.	Select	

B. Risk of Stock out and Expiry

Based on the most up-to-date stock situation, are there any risks of stock-outs or expiries for the key pharmaceuticals and health products listed below at the central level in the next Reporting Period? If yes, please comment

Key Pharmaceuticals & health products	Risk of expiry	Risk of stock out	Comments
1. Anti-malaria medicines	Select	Select	
2. Bed nets	Select	Select	
3. In-Vitro Diagnostic Products (core/main products only)	Select	Select	
4. Condoms	Select	Select	
5. Anti-retrovirals (provide info for core/main ARV products used to treat 70% of the people on treatment)	Select	Select	
6. Anti-TB medicines (main first, and second line formulations)	Select	Select	
7. Lab supplies (e.g. CD4, Viral Load, Cartridges...)	Select	Select	
8. Other (Please specify in the "Comment" column)	Select	Select	

PSCM & Grant Management

* These sections applies to High Impact and Core portfolios for GC7 only.

Health Products

Grant & Risk Management

Self-assessment

C. Quantification and Forecast

Item	Product categories selected for annual quantification	Target date for quantification completion (1st quantification cycle)	Selected for 2nd quantification cycle during the period (if applicable)(Yes/No)	Target date for quantification completion (2nd quantification cycle, if applicable)	Quantification updated during IP (1st quantification cycle) (Yes/No)	Quantification updated on (date) (1st quantification cycle)	Quantification updated during IP (2nd quantification cycle) (Yes/No)	Quantification updated on (date) (2nd quantification cycle)	Average number of days between planned and actual quantification completion dates	Provide specific comments on delays of more than 3 months
1	ARVs	05-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
2	TB medicines for Sensitive TB	15-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
3	TB medicines for Resistant TB	15-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
4	Antimalaria medicines - treatment	10-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
5	RDTs for HIV	03-May-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
6	Opioid substitute medicines	05-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
7	GeneXpert - Equipment & cartridges for TB program	15-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	
8	Culture/DST/LPA - Equipment & reagents	15-Apr-24	☐ Yes ☒ No		☐ Yes ☒ No	dd-MMM-yy	☐ Yes ☒ No	dd-MMM-yy	120	

D. Grant Procurement Planning Performance

Item	Tracer products selected for grant procurement planning indicator	Planned order placement date according to Health Products Management Template or procurement plan (quarter)	Actual order placement date during reporting period (Q1-Q4)	Order placed according to plan (Yes/No)	Score calculation-tracer product(s) procured as per the plan (Yes=1 / No=0)	Provide specific comments on order placement less than 3 months
1	Methadone-opioid substitute 10mg/ml oral concentrate 1 Liter	Q2-24	Select	☐ Yes ☒ No	0	
2	Dolutegravir/Lamivudine/Tenofovir 50/300/300mg tablet 30 - no carton	Q2-24	Select	☐ Yes ☒ No	0	
3	Rapid Diagnostic Test - HIV HIV 1/2 - SD Bioline 3.0 Kit - no accessories - 30 tests	Q2-24	Select	☐ Yes ☒ No	0	
4	Artemether/Lumefantrine 20/120mg 24 tablet non-dispersible 30 blister	Q2-24	Select	☐ Yes ☒ No	0	
5	Isoniazid/Rifampicin 75/150mg 28 tablet 24 blister (672)	Q2-24	Select	☐ Yes ☒ No	0	
6	Ethambutol/Isoniazid/Pyrazinamide/Rifampicin 275/75/400/150mg 28 tablet 24 blister (672)	Q2-24	Select	☐ Yes ☒ No	0	
7	GeneXpert - Equipment & cartridges GeneXpert ULTRA Cartridge 50	Q2-24	Select	☐ Yes ☒ No	0	

* Section E applies to **High Impact and Core** portfolios for GC7 only.

Health Products

Grant & Risk
Management

Self-assessment

E. Central Stock Level (Stocked According to Plan)

Item	Tracer products selected for stocked to plan indicator	Minimum stock level (months of stock)	Maximum stock level (months of stock)	All stocked to plan during the reporting period (Yes/No)	Data source	Stock on hand in packs	Average Monthly Consumption (AMC) in packs	Actual reported stock levels in months of stock	Score calculation-Tracer product(s) within stock plan (Yes=1 / No=0)	PR comments
1	Methadone-opioid substitute 10mg/ml oral concentrate 1 Liter	4	6	☐ Yes ☒ No	Select			0	0	
2	Dolutegravir/Lamivudine/Tenofovir 50/300/300mg tablet 30 - no carton	4	6	☐ Yes ☒ No	Select			0	0	
3	Rapid Diagnostic Test - HIV HIV 1/2 - SD Bioline 3.0 Kit - no accessories - 30 tests	4	6	☐ Yes ☒ No	Select			0	0	
4	Artemether/Lumefantrine 20/120mg 24 tablet non-dispersible 30 blister	4	6	☐ Yes ☒ No	Select			0	0	
5	Isoniazid/Rifampicin 75/150mg 28 tablet 24 blister (672)	4	6	☐ Yes ☒ No	Select			0	0	
6	Ethambutol/Isoniazid/Pyrazinamide/Rifampicin 275/75/400/150mg 28 tablet 24 blister (672)	4	6	☐ Yes ☒ No	Select			0	0	
7	GeneXpert - Equipment & cartridges GeneXpert ULTRA Cartridge 50	4	6	☐ Yes ☒ No	Select			0	0	

F. Additional Information

	PR comments
Comment on additional issues related to the procurement and supply management of pharmaceuticals and health products. Provide information to aid in the interpretation of the results, including context on factors within and beyond the PR's control.	

A. Grant Requirements ⓘ

Item	Description	PR Progress Status	PR comment on implementation progress
1		Select	

B. Mitigating Actions and Management Issues

Item	Sub Risk	Completion Due Date	Mitigating Action	KMA	PR Progress Status	PR Completion Date (if status is completed)	PR comment on implementation progress
1				Yes	Select	dd-MMM-yy	
2				No	Select	dd-MMM-yy	

Self Assessment

> Errors and Warnings

≡ Check data quality

PR Self Assessment

Provide a summary of grant management performance (integrating programmatic, finance, procurement, supply chain management, grant and risk management consideration) during the current reporting period

Explain any external factors beyond the control of the Principal Recipient that have negatively impacted quality and timely grant delivery during the reporting period.

Principal Recipient forward-looking assessment / prospective outlook on grant delivery by module for the coming reporting period

Item	Module	PR response	Forward-looking assessment of performance per module, with focus on key interventions
1	Case management	Select	
2	Vector control	Select	
3	Prevention package for people who use drugs (PUD) and their sexual partners	Select	
4	Prevention package for people in prisons and other closed settings	Select	
5	Differentiated HIV Testing Services	Select	
6	Treatment, care and support	Select	
7	TB/HIV	Select	
8	TB diagnosis, treatment and care	Select	
9	Drug-resistant (DR)-TB diagnosis, treatment and care	Select	
10	TB/DR-TB Prevention	Select	
11	Key and vulnerable populations (KVP) – TB/DR-TB	Select	
12	RSSH: Monitoring and evaluation systems	Select	
13	RSSH/PP: Laboratory systems (including national and peripheral)	Select	

Foreseen changes in the grant, if any